tradingkey.logo

60 Degrees Pharmaceuticals Inc

SXTP
4.160USD
+0.310+8.05%
Fechamento 02/06, 16:00ETCotações atrasadas em 15 min
4.27MValor de mercado
3.70P/L TTM

60 Degrees Pharmaceuticals Inc

4.160
+0.310+8.05%

Mais detalhes de 60 Degrees Pharmaceuticals Inc Empresa

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.

Informações de 60 Degrees Pharmaceuticals Inc

Código da empresaSXTP
Nome da Empresa60 Degrees Pharmaceuticals Inc
Data de listagemJul 12, 2023
CEODow (Geoffrey S)
Número de funcionários3
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 12
Endereço1025 Connecticut Avenue Nw
CidadeWASHINGTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal20036
Telefone12023275422
Sitehttps://60degreespharma.com/
Código da empresaSXTP
Data de listagemJul 12, 2023
CEODow (Geoffrey S)

Executivos da empresa 60 Degrees Pharmaceuticals Inc

Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Geoffrey S. Dow, Ph.D.
Dr. Geoffrey S. Dow, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.36K
+5659.00%
Ms. Cheryl Xu
Ms. Cheryl Xu
Director
Director
3.95K
+1750.00%
Mr. Tyrone Miller
Mr. Tyrone Miller
Chief Financial Officer
Chief Financial Officer
1.32K
--
Ms. Kristen Landon
Ms. Kristen Landon
Chief Commercial Officer
Chief Commercial Officer
1.14K
--
Mr. Charles W. Allen
Mr. Charles W. Allen
Independent Director
Independent Director
59.00
--
Dr. Stephen Toovey
Dr. Stephen Toovey
Independent Director
Independent Director
59.00
--
Mr. Paul Field
Mr. Paul Field
Independent Director
Independent Director
59.00
--
Mr. Patrick Gaynes
Mr. Patrick Gaynes
Investor Relations Officer
Investor Relations Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Geoffrey S. Dow, Ph.D.
Dr. Geoffrey S. Dow, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.36K
+5659.00%
Ms. Cheryl Xu
Ms. Cheryl Xu
Director
Director
3.95K
+1750.00%
Mr. Tyrone Miller
Mr. Tyrone Miller
Chief Financial Officer
Chief Financial Officer
1.32K
--
Ms. Kristen Landon
Ms. Kristen Landon
Chief Commercial Officer
Chief Commercial Officer
1.14K
--
Mr. Charles W. Allen
Mr. Charles W. Allen
Independent Director
Independent Director
59.00
--
Dr. Stephen Toovey
Dr. Stephen Toovey
Independent Director
Independent Director
59.00
--

Detalhamento da receita

Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.

Distribuição de ações

Atualizado em: qua, 21 de jan
Atualizado em: qua, 21 de jan
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Orca Capital GmbH
3.23%
Dow (Geoffrey S)
0.88%
Knight Therapeutics, Inc.
0.66%
DRW Securities, LLC
0.49%
Xu (Cheryl)
0.31%
Outro
94.43%
Investidores
Investidores
Proporção
Orca Capital GmbH
3.23%
Dow (Geoffrey S)
0.88%
Knight Therapeutics, Inc.
0.66%
DRW Securities, LLC
0.49%
Xu (Cheryl)
0.31%
Outro
94.43%
Tipos de investidores
Investidores
Proporção
Investment Advisor
3.72%
Individual Investor
1.39%
Corporation
0.66%
Investment Advisor/Hedge Fund
0.24%
Hedge Fund
0.06%
Bank and Trust
0.03%
Outro
93.89%

Participação acionária institucional

Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
25
52.23K
4.06%
-28.54K
2025Q3
22
451.55K
11.00%
+385.44K
2025Q2
28
103.95K
3.22%
+2.41K
2025Q1
28
93.99K
6.38%
-12.96K
2024Q4
26
104.62K
14.10%
+11.58K
2024Q3
25
101.03K
25.05%
+54.30K
2024Q2
23
54.29K
27.13%
-3.10K
2024Q1
19
57.35K
31.08%
+1.78K
2023Q4
19
60.17K
63.69%
+30.80K
2023Q3
18
63.13K
66.75%
+44.65K

Atividade dos acionistas

Nome
Ações detidas
Proporção
Variação
Var. %
Data
Orca Capital GmbH
166.23K
3.93%
+166.23K
--
Jul 16, 2025
Dow (Geoffrey S)
45.42K
1.07%
+22.63K
+99.30%
Dec 15, 2025
Knight Therapeutics, Inc.
33.90K
0.8%
+14.67K
+76.26%
Sep 30, 2024
DRW Securities, LLC
25.21K
0.6%
+25.21K
--
Sep 30, 2025
Xu (Cheryl)
15.82K
0.37%
+7.00K
+79.40%
Aug 26, 2025
Geode Capital Management, L.L.C.
12.45K
0.29%
-67.00
-0.54%
Sep 30, 2025
Miller (Tyrone)
5.27K
0.12%
--
--
Aug 26, 2025
Landon (Kristen)
4.54K
0.11%
--
--
Aug 26, 2025
Tower Research Capital LLC
3.14K
0.07%
+542.00
+20.86%
Sep 30, 2025
UBS Switzerland AG
1.48K
0.03%
+1.48K
--
Sep 30, 2025
Ver Mais

ETFs Relacionados

Nome
Proporção
Sem dados

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados

Desdobramento de ações

Data
Data ex-dividendo
Tipo
Proporção
Jan 15, 2026
Merger
4→1
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Aug 06, 2024
Merger
12→1
Data
Data ex-dividendo
Tipo
Proporção
Jan 15, 2026
Merger
4→1
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Aug 06, 2024
Merger
12→1
Aug 06, 2024
Merger
12→1
Aug 06, 2024
Merger
12→1
Aug 06, 2024
Merger
12→1
KeyAI